Clinical trial · Observational
Protein Kinase A in Prostate Cancer Tissue.
Assessment of the Expression and Activity of Protein Kinase A in Prostate Cancer Tissue
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prostate cancer is the most common malignancy in men. documented risk factors of prostate cancer are age, ethnicity, various genomic mutations and family history of prostate cancer. The cellular mechanisms of malignant transformation are numerous and not completely understood. A possible mechanism is induction of an inflammation resulting in cellular atypia and pre-malignant changes in the affected tissue by inducing a pro-inflammatory response or changes in extra cellular matrix. Protein Kinase A (PKA) is a key stone enzyme in various intra-cellular processes. Various infections' inflammations and malignancies were proved to impact PKA activity. The research hypothesis is that prostate cancer tissue will show a unique profile of PKA activity, regulation and intracellular distribution.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Benign Hyperplasia of Prostate | Benign Prostatic Hyperplasia | ALIAS | 0.90 |
| Inflammation | — | UNRESOLVED | — |
| Prostate Neoplasm | Prostate Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| prostate biopsy | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The distribution of PKA in prostate cancer versus benign tissue
- timeFrame
- 1 year
- description
- Immunohistochemical staining of paraffin sections of prostatebiopsies for PKA, western blot analysisi of tissue.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Men * Clinical suspicion of prostate cancer * Referred for biopsy * Able to sign informed consent. Exclusion Criteria: * Previous prostate irradiation * Chronic prostatitis * Previous prostate surgery * Recent urinary tract infection (3 months prior to biopsy). * Indwelling urinary catheter
References
Publications (0)
Data not yet available